- en: <!--yml
  id: totrans-split-0
  prefs: []
  type: TYPE_NORMAL
  zh: <!--yml
- en: 'category: 未分类'
  id: totrans-split-1
  prefs: []
  type: TYPE_NORMAL
  zh: 'category: 未分类'
- en: 'date: 2024-05-27 14:42:12'
  id: totrans-split-2
  prefs: []
  type: TYPE_NORMAL
  zh: 'date: 2024-05-27 14:42:12'
- en: -->
  id: totrans-split-3
  prefs: []
  type: TYPE_NORMAL
  zh: -->
- en: Single dose of LSD provides immediate, lasting anxiety relief, study says |
    CNN
  id: totrans-split-4
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
  zh: 一剂LSD提供即时持久的焦虑缓解，研究称 | CNN
- en: 来源：[https://www.cnn.com/2024/03/07/health/lsd-anxiety-fda-breakthrough-therapy-wellness/index.html](https://www.cnn.com/2024/03/07/health/lsd-anxiety-fda-breakthrough-therapy-wellness/index.html)
  id: totrans-split-5
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
  zh: 来源：[https://www.cnn.com/2024/03/07/health/lsd-anxiety-fda-breakthrough-therapy-wellness/index.html](https://www.cnn.com/2024/03/07/health/lsd-anxiety-fda-breakthrough-therapy-wellness/index.html)
- en: CNN  —
  id: totrans-split-6
  prefs: []
  type: TYPE_NORMAL
  zh: CNN —
- en: A clinical trial’s encouraging results won US Food and Drug Administration breakthrough
    therapy status for an [LSD](https://www.cnn.com/2020/02/27/health/lsd-overdoses-case-studies-wellness/index.html) formulation
    to treat generalized anxiety disorder, Mind Medicine Inc. announced Thursday.
    The biopharmaceutical company is developing the drug.
  id: totrans-split-7
  prefs: []
  type: TYPE_NORMAL
  zh: 一项临床试验的鼓舞人心的结果使一种[LSD](https://www.cnn.com/2020/02/27/health/lsd-overdoses-case-studies-wellness/index.html)制剂获得了美国食品和药物管理局的突破性疗法地位，用于治疗广泛焦虑障碍，Mind
    Medicine Inc.周四宣布。这家生物制药公司正在开发这种药物。
- en: “A breakthrough designation is a recognition that a drug has demonstrated evidence
    of clinical efficacy in meeting an unmet medical need with morbidity and mortality
    associated with it,” said Dr. Daniel Karlin, assistant professor of psychiatry
    at Tufts University School of Medicine in Boston and chief medical officer for
    MindMed.
  id: totrans-split-8
  prefs: []
  type: TYPE_NORMAL
  zh: “突破性认定是药物已经证明在满足未满足的医疗需求中具有临床疗效的承认，这些需求与相关的发病率和死亡率有关，”波士顿塔夫茨大学医学院精神病学助理教授、MindMed首席医务官丹尼尔·卡林博士说道。
- en: MindMed’s MM120 will still go through the standard FDA approval process, including
    phase III trials.
  id: totrans-split-9
  prefs: []
  type: TYPE_NORMAL
  zh: MindMed的MM120仍将按照标准的FDA批准流程进行，包括第三阶段试验。
- en: The designation, however, “is an offer from the agency to engage more closely
    in drug development,” Karlin said. “It affects timelines of response and our ability
    to get more interactions with the agency so that we can be sure that we’re in
    lockstep agreement as we move forward.”
  id: totrans-split-10
  prefs: []
  type: TYPE_NORMAL
  zh: 然而，“这一称号是机构提出更密切参与药物开发的建议，” Karlin说道。“它影响了响应时间表和我们与机构进一步互动的能力，以便我们确保在推进过程中完全一致。”
- en: 'Two other companies have also received FDA breakthrough therapy status: [psilocybin](https://compasspathways.com/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/)
    for treatment-resistant depression and to [MDMA,](https://maps.org/news/media/press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd-agrees-on-special-protocol-assessment-for-phase-3-trials/)
    (3,4-Methyl​enedioxy​methamphetamine) commonly known as ecstasy or molly, for
    post-traumatic stress disorder or PTSD.'
  id: totrans-split-11
  prefs: []
  type: TYPE_NORMAL
  zh: 另外两家公司也获得了FDA的突破性疗法地位：[卡西洛](https://compasspathways.com/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/)用于治疗顽固性抑郁症和[MDMA](https://maps.org/news/media/press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd-agrees-on-special-protocol-assessment-for-phase-3-trials/)（3,4-亚甲基二氧苯丙胺），通常称为迷幻药或摇头丸，用于创伤后应激障碍或PTSD。
- en: A single dose of MM120 (lysergide d-tartrate) led to a 48% rate of remission
    from generalized anxiety disorder at 12 weeks following the drug’s administration,
    according to MindMed.
  id: totrans-split-12
  prefs: []
  type: TYPE_NORMAL
  zh: 一剂MM120（d-酒石酸麦角胺）在药物施用后12周导致广泛焦虑障碍的缓解率达到48％，据MindMed报道。
- en: The MM120 drug also significantly improved clinical signs of [generalized anxiety
    disorder](https://www.cnn.com/2022/04/01/health/social-anxiety-cognitive-behavioral-therapy-benefits-wellness/index.html)
    for 65% of patients within three months, according to results of the phase 2b
    trial designed to test dosage levels, the company said.
  id: totrans-split-13
  prefs: []
  type: TYPE_NORMAL
  zh: MM120药物还显著改善了65％的患者在三个月内的[广泛焦虑障碍](https://www.cnn.com/2022/04/01/health/social-anxiety-cognitive-behavioral-therapy-benefits-wellness/index.html)的临床症状，根据旨在测试剂量水平的2b期试验结果，公司称。
- en: Anxiety is the most [common mental disorder](https://www.cnn.com/2022/10/07/health/anxiety-mental-health-depression-screening-prevention-health-wellness/index.html)
    in the United States, affecting over 40 million people age 18 and older each year,
    according to the [Anxiety and Depression Association of America.](https://adaa.org/understanding-anxiety/facts-statistics)
    Generalized anxiety order is characterized by excessive, ongoing thoughts that
    are difficult to control and interfere with day-to-day activities.
  id: totrans-split-14
  prefs: []
  type: TYPE_NORMAL
  zh: 根据美国焦虑与抑郁协会的数据，焦虑是美国最常见的心理障碍，每年影响超过4000万名18岁及以上的人群。广泛性焦虑障碍表现为难以控制且干扰日常活动的过度持续思维。
- en: “The clinical improvement for many patients was more than double what we see
    with today’s standard of care,” Karlin said. “This occurred at all levels of anxiety,
    from moderate all the way up to severe.”
  id: totrans-split-15
  prefs: []
  type: TYPE_NORMAL
  zh: “许多患者的临床改善超过了今天的标准治疗水平的两倍以上，”Karlin说。“这种情况发生在从中度焦虑到严重焦虑的所有水平。”
- en: Standard of care for generalized anxiety disorder is a combination of [cognitive
    behavioral therapy](https://www.cnn.com/2021/11/27/health/cbt-cognitive-behavioral-therapy-wellness/index.html)
    and medications such as selective serotonin reuptake inhibitors, or SSRIs, and
    buspirone — both of which work on levels of serotonin in the brain — as well as
    sedatives called benzodiazepines.
  id: totrans-split-16
  prefs: []
  type: TYPE_NORMAL
  zh: 广泛焦虑障碍的标准治疗是认知行为疗法和选择性血清素再摄取抑制剂（SSRI）及丁螺环酮等药物的组合，这两者都通过调节大脑中的5-羟色胺水平发挥作用，以及称为苯二氮䓬类药物的镇静剂。
- en: All of these medications need time to work and may require experimentation with
    various doses, adding time and expense to a patient’s treatment, Karlin said.
  id: totrans-split-17
  prefs: []
  type: TYPE_NORMAL
  zh: 所有这些药物都需要时间发挥作用，并可能需要尝试不同剂量，这增加了患者治疗的时间和费用，Karlin说。
- en: The multicenter, randomized, double-blinded trial tested doses of 25, 50, 100
    and 200 micrograms compared with a placebo.
  id: totrans-split-18
  prefs: []
  type: TYPE_NORMAL
  zh: 这项多中心、随机、双盲试验测试了25、50、100和200微克的剂量与安慰剂的比较。
- en: “We’re very confident based on the results that 100 micrograms is the right
    dose to bring into our phase three studies, as we didn’t see any more improvement
    with 200 micrograms but did see additional adverse effects,” Karlin said.
  id: totrans-split-19
  prefs: []
  type: TYPE_NORMAL
  zh: “基于结果，我们非常有信心认为100微克是进入我们的第三阶段研究的正确剂量，因为我们在200微克剂量下没有看到更多的改善，但确实看到了额外的不良反应”，Karlin说道。
- en: Professor David Nutt, director of the Neuropsychopharmacology Unit at Imperial
    College London’s division of brain sciences, who researches psychedelics, said
    in an email that the study results “are very exciting data in what can be a difficult
    to treat population (anxiety).”
  id: totrans-split-20
  prefs: []
  type: TYPE_NORMAL
  zh: 伦敦帝国理工学院大脑科学部神经精神药理学单位主任、研究迷幻药的David Nutt教授在一封电子邮件中表示，研究结果“在一个难以治疗的人群（焦虑症）中是非常激动人心的数据”。
- en: “They expand the likely utility of [psychedelic treatment](https://www.cnn.com/2020/01/24/health/goop-psychedelics-wellness/index.html)
    beyond depression,” said Nutt, who was not involved in the research. “And again,
    [as with the depression trials](https://www.cnn.com/2022/11/02/health/psilocybin-magic-mushroom-depression-wellness/index.html),
    a single dose produces enduring effects, probable due to its breaking down persistent
    negative thought processes.”
  id: totrans-split-21
  prefs: []
  type: TYPE_NORMAL
  zh: “它们扩展了[迷幻疗法的可能应用](https://www.cnn.com/2020/01/24/health/goop-psychedelics-wellness/index.html)，超越了抑郁症，”未参与研究的Nutt教授说。“并且，如同抑郁研究一样，单剂量产生持久效果，可能是因为它打破了持续的消极思维过程。”
- en: While it was not the study’s primary purpose, results did show that MM120 also
    improved [signs of depression,](https://www.cnn.com/videos/health/2023/06/14/magic-mushroom-david-culver-ron-2-actws-vpx.cnn) Karlin
    said. “We saw rapid and robust improvement on depression symptoms in people —
    depression and anxiety have overlapping disease definitions.”
  id: totrans-split-22
  prefs: []
  type: TYPE_NORMAL
  zh: 尽管这不是研究的主要目的，结果显示MM120也改善了[抑郁症状](https://www.cnn.com/videos/health/2023/06/14/magic-mushroom-david-culver-ron-2-actws-vpx.cnn)，Karlin说。“我们看到人们的抑郁症状迅速而强劲地改善
    — — 抑郁症和焦虑症有重叠的疾病定义。”
- en: Most research with MDMA and psilocybin has relied on the use of trained therapists
    who meet and establish a rapport with participants before the drug is administered.
    Those therapists are then on hand during the “trip” to help each person assimilate
    the experience, thus helping assure the lasting impact of any psychological insights.
  id: totrans-split-23
  prefs: []
  type: TYPE_NORMAL
  zh: 大多数MDMA和psilocybin的研究依赖于使用经过训练的治疗师，在药物被施用之前与参与者会面并建立关系。这些治疗师在“旅程”期间随时待命，帮助每个人消化经历，从而确保任何心理洞察的持久影响。
- en: The MM120 study, however, was accomplished without the use of psychotherapy
    during the session. Instead, monitors sat in the room to assure safety, but spent
    their time “mostly reading books,” Karlin said.
  id: totrans-split-24
  prefs: []
  type: TYPE_NORMAL
  zh: 然而，MM120研究在会话期间没有使用心理治疗。相反，监控人员坐在房间里以确保安全，但大部分时间“主要是看书”，Karlin说。
- en: “While prior research has documented the benefits of combining LSD with psychotherapy
    to alleviate anxiety associated with life-threatening conditions, this groundbreaking
    study is the first to show that a single dose of LSD … can effectively treat generalized
    anxiety without the adjunct of psychotherapy,” said psychiatrist Dr. Gabriella
    Gobbi, a professor and scientist at McGill University Health Centre in Montreal
    and Canada Research Chair in Therapeutics for Mental Health. She was not involved
    in the clinical trial.
  id: totrans-split-25
  prefs: []
  type: TYPE_NORMAL
  zh: “虽然先前的研究已经记录了将LSD与心理治疗结合以减轻与威胁生命条件相关的焦虑的好处，但这项开创性研究是首次表明，单剂量的LSD……可以有效治疗广泛性焦虑而无需辅助心理治疗，”蒙特利尔麦吉尔大学健康中心的精神科医生、教授和科学家Gabriella
    Gobbi博士说。她没有参与临床试验。
- en: Compared with experiences with forms of LSD purchased illegally on the street,
    the study’s grade of MM120 did not appear to induce “bad trips,” Karlin said.
  id: totrans-split-26
  prefs: []
  type: TYPE_NORMAL
  zh: 与街头非法购买的LSD形式的经历相比，研究中的MM120等级似乎没有诱发“坏旅程”，Karlin说。
- en: “LSD is difficult to manufacture with high purity and tends to degrade quickly
    in the presence of light and water,” Karlin said. “We’re manufacturing it to pharmaceutical
    industry standards, a highly pure version that is also shelf stable. So that’s
    a critical difference.”
  id: totrans-split-27
  prefs: []
  type: TYPE_NORMAL
  zh: “LSD难以高纯度制造，并且在光和水的存在下很快降解，”Karlin说。“我们正在按照制药行业标准进行制造，这是一个高纯度且具有货架稳定性的版本。因此这是一个关键的区别。”
- en: Most adverse effects in the study were rated as mild to moderate by participants,
    occurring mostly on the day of the study, Karlin said. Those included euphoric
    feelings, illusions and hallucinations, anxiety, abnormal thinking, headaches,
    dizziness, nausea, excessive sweating, vomiting, numbness or tingling of the skin,
    and pupil dilation.
  id: totrans-split-28
  prefs: []
  type: TYPE_NORMAL
  zh: 大多数研究中的不良反应被参与者评为轻到中度，主要发生在研究当天，Karlin说。这些包括欣快感、错觉和幻觉、焦虑、异常思维、头痛、眩晕、恶心、过度出汗、呕吐、皮肤麻木或刺痛以及瞳孔扩张。
- en: When the MM120 clinical trial began in August 2022, it marked the first time LSD
    had been studied in a medical setting in over 40 years, Karlin said.
  id: totrans-split-29
  prefs: []
  type: TYPE_NORMAL
  zh: 当2022年8月MM120临床试验开始时，这标志着LSD在医疗环境中首次研究超过40年，Karlin说。
- en: During the 1940s and early 1950s, [tens of thousands of patients](https://www.ncjrs.gov/App/abstractdb/AbstractDBDetails.aspx?id=185048) took
    LSD and other psychotropics to[ study their effects](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603820/#bib61) on
    cancer anxiety, alcoholism, opioid use disorder, depression, and post-traumaticstress
    disorder or PTSD. Researchers began to see psychedelics as possible “[new tools
    for shortening psychotherapy](https://www.ncbi.nlm.nih.gov/pubmed/14793387).”
  id: totrans-split-30
  prefs: []
  type: TYPE_NORMAL
  zh: 在1940年代和1950年代初，数万名患者服用LSD和其他精神药物以研究其对癌症焦虑、酒精中毒、阿片类药物使用障碍、抑郁症和创伤后应激障碍（PTSD）的影响。研究人员开始将致幻剂视为可能的“缩短心理治疗时间的新工具”。
- en: But when Harvard University psychologists Timothy Leary and Richard Alpert were
    fired from the [Harvard Psilocybin Project](https://psychology.fas.harvard.edu/people/timothy-leary) in
    1963  after the university discovered they had been giving LSD to their students,
    the use of psychedelics for research began to lose its luster.
  id: totrans-split-31
  prefs: []
  type: TYPE_NORMAL
  zh: 但是，当哈佛大学心理学家蒂莫西·利里和理查德·阿尔佩特在1963年因为大学发现他们向学生施用LSD而被解雇后，用于研究的致幻剂开始失去其光彩。
- en: Leary began to speak out publicly, encouraging young people to take LSD recreationally.
    He quickly became the face of the drug counterculture movement with his [signature
    message](https://www.youtube.com/watch?v=LTCxINKT7l4), “Turn on, tune in, drop
    out.”
  id: totrans-split-32
  prefs: []
  type: TYPE_NORMAL
  zh: 利里开始公开发声，鼓励年轻人娱乐性地使用LSD。他很快成为以他的[标志性信息](https://www.youtube.com/watch?v=LTCxINKT7l4)“开启、调整、退出”的毒品反文化运动的代表面孔。
- en: No longer administered solely in the relative safety of a lab or psychiatrist’s
    office, LSD began to feature in horror stories of bad “acid” trips at colleges
    and concerts — headlines that appeared alongside images of anti-Vietnam protests
    and Woodstock attendees.
  id: totrans-split-33
  prefs: []
  type: TYPE_NORMAL
  zh: LSD不再仅限于实验室或精神科医生办公室的相对安全环境中使用，开始在大学和音乐会上成为恐怖“迷幻剂”旅行的恶劣故事的主角 —— 这些头条新闻与反越南战争抗议活动和伍德斯托克参与者的形象并列出现。
- en: In 1968, the United States outlawed LSD and research projects were shut down
    or forced underground. Then came the 1970 Controlled Substances Act, signed by
    President Richard Nixon. It classified all hallucinogenics, including psilocybin,
    as [Schedule I drugs](https://www.dea.gov/drug-scheduling) — substances with “no
    currently accepted medical use” and a high probability of abuse.
  id: totrans-split-34
  prefs: []
  type: TYPE_NORMAL
  zh: 1968年，美国取缔了LSD，并关闭或迫使地下化研究项目。然后是1970年由理查德·尼克松总统签署的《受控物质法案》。该法案将包括赛洛西宾在内的所有致幻剂归类为[I类药物](https://www.dea.gov/drug-scheduling)，即“目前没有被批准的医疗用途”且极易滥用的物质。
- en: '*Clarification: This story has been updated to more precisely reflect the FDA
    approval process.*'
  id: totrans-split-35
  prefs: []
  type: TYPE_NORMAL
  zh: '*澄清：此故事已更新，以更准确地反映FDA的批准过程。*'
